STERLING WINTHROP'S PHARMACEUTICALS UNIT, SANOFI WINTHROP, LAUNCHES PRIMACOR I.V. IN THE U.S.
STERLING WINTHROP'S PHARMACEUTICALS UNIT, SANOFI WINTHROP, LAUNCHES PRIMACOR I.V. IN THE U.S. NEW YORK, Oct. 19 /PRNewswire/ -- Sterling Winthrop Inc. today announced that Sanofi Winthrop Pharmaceuticals will enter the U.S. market with PRIMACOR(R) I.V. (milrinone lactate), an intravenous agent for the short-term treatment of congestive heart failure (CHF). Clinical experience demonstrates that Primacor I.V. produces rapid, sustained improvements in the performance of the heart and the circulation to help patients with congestive heart failure. CHF is a mechanical inadequacy of the heart whereby its function as a pump fails to maintain adequate circulation of the blood, with the result that congestion and edema -- accumulation of fluids -- develop in the tissues of the heart and throughout the body. CHF may result from a number of underlying causes, including hypertension, myocardial infarction, insufficient supply of oxygen to cardiac tissue, defective heart valves or various diseases of the myocardium. Primacor I.V. therapy is beneficial to patients with CHF. "Primacor I.V. offers a new therapy for acutely ill CHF patients," said Jaime Coehlo, M.D., senior associate medical director, Sanofi Winthrop Pharmaceuticals. "It helps the heart pump more strongly and dilates the blood vessels to reduce resistance, resulting in improved circulatory function." When faced with rapid worsening of chronic CHF, medical teams must switch from oral to intravenous therapy with potent drugs in an attempt to stabilize hemodynamics over the short run and restore the patient baseline status to that preceding the episode. Primacor I.V., a PDE III inhibitor, helps medical teams to achieve this goal. Key products among the portfolio of pharmaceuticals marketed by Sanofi Winthrop Pharmaceuticals in the U.S. are Omnipaque(R) (iohexol) injection, a leading nonionic contrast agent (in the U.S. and Canada); Inocor(R) (intravenous amrinone) injection, for congestive heart failure; Talwin(R) Nx (pentazocine and naloxone hydrochloride) tablets, an analgesic; Carpuject(R) line of injectables in pre-filled syringes; and Plaquenil(R) (hydroxychloroquine) tablets, for rheumatoid arthritis and lupus erythematosus. Headquartered in New York, Sterling Winthrop Inc. is a leading manufacturer and marketer of pharmaceutical and consumer health products. -0- 10/19/92 /CONTACT: Diane C. Iselin, 212-907-2341; or Terry G. Kelley, 212-907-3009, both of Sterling Winthrop Inc./ CO: Sterling Wihthrop Inc.; Sanofi Winthrop Pharmaceuticals ST: New York IN: MTC SU:
TS-EE -- NY034 -- 1698 10/19/92 14:18 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 19, 1992|
|Previous Article:||MERRILL LYNCH BUSINESS BROKERAGE AND VALUATION SAYS NUMBER OF MERGERS AND ACQUISITIONS ANNOUNCED IN THE 1992 THIRD QUARTER UP 36 PERCENT|
|Next Article:||AWWA ANNOUNCES EIGHTY PERCENT OF WATER UTILITIES FALL WITHIN SAFETY STANDARDS FOR LEAD|